Abstract
Pancreatic adenocarcinoma remains a widespread and difficult disease to treat. Surgical resection offers the possibility of cure in a select few. However, most patients are not eligible, and conventional chemotherapy and radiation remain largely ineffective. Despite this, our understanding of the pathogenesis of the disease has advanced considerably over the past few decades. These findings provide the basis for the development of much needed new therapeutic modalities. Specifically, the application of new recombinant DNA technology and techniques to pancreatic cancer has yielded promising results. This paper reviews our current understanding of the molecular biology of pancreatic adenocarcinoma and its applications to the field of gene therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
